ClinicalTrials.gg
RecruitingNCT07377487INDIGOUpdated Oct 21, 2026

TheraSphere Japan Pre-Market Study

An interventional study of TheraSphere Y-90 glass microsphere in Liver Neoplasms, sponsored by Boston Scientific Corporation. Recruiting at 5 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Sep 25, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 41 studies in Liver Neoplasms with a site in Japan — 5 open to participants now, 12 under way, 4 of them phase 3. Liver Neoplasms · Japan.

Planned enrollment
29th of 34
51 · median 209
Started
2026
the only one that year
No phase
3 of 41
1 open now
Primary completion
2027-06
later than 7 of 11 live
Registered
40th of 41
by date
Lead sponsor
1 of 41
Boston Scientific Corporation

Among the 41 studies in Liver Neoplasms with a site in Japan, this one is the 29th largest by planned enrollment of the 34 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 40th registered.

Liver Neoplasms

1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

5 of the 41 studies in Liver Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Liver Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.

03

Conditions studied

  • Liver Neoplasms

Keywords

  • Carcinoma
  • Carcinoma, Hepatocellular
  • Neoplasms
  • Digestive System Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Neoplasms by Site
  • Digestive System Diseases
  • Liver Diseases
  • Neoplasm Metastasis
  • Colorectal Neoplasms
  • Colonic Diseases
  • Carcinoma, Neuroendocrine
  • Neuroendocrine Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

[Inclusion criteria based on the clinical evaluation]

  1. Patient aged >18 years at time of consent
  2. Patient is able and willing to participate in the study and has provided written
  3. Patient who is determined to have failed or not be eligible for standard treatment by the multidisciplinary board
  4. Primary or secondary liver cancer (by histology or imaging)
  5. defined as at least one uni-dimensional measurable liver lesion by CT/MRI (according to 1.1)
  6. Liver dominant disease (patient prognosis is driven by liver tumor)
  7. Tumor replacement \<50% of total liver volume based on visual estimation by the investigator
  8. Expected ≥ 3 months or more from the index procedure
  9. Performance Status score of 0 or 1
  10. Negative pregnancy test in women of
  11. Adequate for the patient and his/her sexual partner when applicable.
  12. Adequate liver function, as defined by:

    • A or to B7 (HCC)
    • Must have ≤ 2 mg/dL
    • and AST must be \<5 x
    • Albumin ≥3.0 g/dL
  13. Adequate renal function, as defined by:

    • Serum creatinine must be ≤1.5 x ULN
  14. Adequate hematological function, as defined by:

    • > 1200 /mm3
    • ≥85 mg/L
    • count >50 x 109/L
    • must be \<2.0 or >50% prothrombin activity

    [Inclusion Criteria based on the imaging evaluation]

  15. After 99mTc MAA administration, in SPECT/CT imaging, good PVT targeting and uptake of 99mTc MAA, if present
  16. Future liver remnant volume (FLRV) >30% of whole liver volume. FRLV is the volume of liver not planned to be treated with TheraSphere and free of tumor

Exclusion criteria

Exclusion Criteria:

[Exclusion Criteria based on the clinical evaluation]

  1. Vp4 according to the Liver Cancer Study Group of Japan (LCSGJ) portal vein tumor thrombosis classification1
  2. History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically.
  3. to angiography and selective visceral catheterization
  4. Received any prior external beam radiation treatment to the liver
  5. Received any prior yttrium-90 microsphere treatment to the liver
  6. Received previous peptide receptor radionuclide therapy (PRRT)
  7. Plan to start systemic anticancer treatment in the next 3 month after the index procedure.
  8. Presence of ongoing adverse event due to prior therapy as judged by the principal investigator or sub-investigator to affect the safety evaluation of the study device.
  9. Evidence of pulmonary insufficiency or clinically evident
  10. Undergone any intervention for, or compromise of, the Ampulla of Vater within that last 3 months or patient with biliodigestive anastomosis.
  11. Presence of ascites, clinical or radiological, "trace" of ascites is acceptable.
  12. Presence of Hepatic encephalopathy (Grade ≥2)
  13. Previous liver function decompensation within the last 6 months (ascites, encephalopathy, jaundice)
  14. Patient with infiltrative disease presentation (not suitable for repeated measurement)
  15. Patients who are pregnant or breast-feeding and does not want to stop.
  16. Have any disease or condition that would preclude the safe use of BSJ019T, including concurrent dialysis treatment, or unresolved serious infections
  17. Participating in concurrent clinical studies or interventional clinical studies
  18. Any condition where the Investigator feels the patient would not be able to participate/finish the study
  19. Previous gastrointestinal bleeding related to portal hypertension within the last 3 months (preventive treatment is acceptable)

    [Exclusion Criteria based on the imaging evaluation]

  20. Dose to the lung > 30Gy for a single treatment or cumulative >50 Gy
  21. Evidence of any off-target extrahepatic and liver deposition on 99mTc-MAA that cannot be corrected using angiographic techniques
  22. Cone Beam CT (CBCT) or 99mTc-MAA hepatic arterial perfusion scintigraphy shows poor tumor perfusion and/or poor tumor targeting that would lead to a dose that does not meet the liver dosing criteria as specify in the protocol
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    TheraSphere

    Device: TheraSphere Y-90 glass microsphere

Interventions

  • DeviceTheraSphere Y-90 glass microsphere

    TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.

06

What researchers measure

Primary outcomes

  1. Rate of hepatic disease control (DCR = complete response [CR], partial response [PR] or stable disease [SD]) at 3 months using the localized RECIST 1.1 criteria.

    Time frame: 3-months post index procedure

Secondary outcomes

  1. Rate of objective response (ORR = complete response [CR] or partial response [PR]) at 3 months using the localized RECIST 1.1 criteria and localized mRECIST

    Time frame: 3-months post index procedure

  2. Rate of hepatic disease control (DCR) and objective response (ORR) at 6 months using localized RECIST 1.1 and localized mRECIST criteria

    Time frame: 6-months post index procedure

  3. Best response using localized RECIST 1.1 and localized mRECIST criteria.

    Time frame: Through 6-months post index procedure

  4. Proportion of patient receiving concomitant and post BSJ019T treatment, including subsequent local and systemic anticancer treatment, surgery, intervention and best supportive care.

    Time frame: Through 6-months post index procedure

  5. Safety assessment: rate of treatment emergent adverse events (TEAEs) of any grade, rate of grade 3 or above TEAEs, rate of SAEs of any causality and rate of SAEs related to treatment with TheraSphere.

    All AEs will be evaluated using the standardized grading criteria (National Cancer Institute- Common Terminology Criteria for Adverse Events- Version 5.0 (NCI-CTCAE v 5.0))

    Time frame: Through 6-months post index procedure

  6. Technical success in delivering the Y-90 microspheres

    Technical success is determined successful if residual waste is ≦2% with optimal tumor targeting and extrahepatic deposition is not seen on post treatment imaging, and the success rate of entire of the subjects will be summarized.

    Time frame: During the index procedure

  7. Health-related quality of life (HRQoL) using EQ-5D questionnaires at regular intervals

    Time frame: Baseline, 1-, 3- and 6-months post treatment

  8. Health-related quality of life (HRQoL) using FACT-G questionnaires at regular intervals

    Time frame: Baseline, 1-, 3- and 6-months post treatment

  9. Overall survival

    Time frame: Through study completion, an average of 1 year

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 168 interventional studies with no phase under Liver Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 72. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Jan 30, 2026
StartActual
Jan 22, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Hyogo College of Medicine Hospital · Nishinomiya, JapanNot yet recruiting→Recruiting
  • Kindai University Hospital · Sayama, JapanNot yet recruiting→Recruiting
  • National Cancer Center Hospital · Chuo Ku, JapanNot yet recruiting→Recruiting
Show site
  • Nara Medical University Hospital · Kashihara, Japan
Sep 25, 2026
Show all 2 updates
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 25, 2026
    1 site added. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Hyogo College of Medicine Hospital · Nishinomiya, JapanNot yet recruiting→Recruiting
    • Kindai University Hospital · Sayama, JapanNot yet recruiting→Recruiting
    • National Cancer Center Hospital · Chuo Ku, JapanNot yet recruiting→Recruiting
    Show site
    • Nara Medical University Hospital · Kashihara, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07377487
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Jan 22, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Satoru Motohashi
Contact
satoru.motohashi@bsci.com
+81(80)4619-9640
Koichiro Yamakado, MD, PhD
principal investigator · Hyogo Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion